Proteasome inhibition as a therapeutic approach in atypical teratoid/rhabdoid tumors

BACKGROUND: Atypical teratoid/thabdoid tumor (AT/RT) remains a difficult-to-treat tumor with a 5-year overall survival rate of 15%–45%. Proteasome inhibition has recently been opened as an avenue for cancer treatment with the FDA approval of bortezomib (BTZ) in 2003 and carfilzomib (CFZ) in 2012. Th...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neurooncol Adv
Autors principals: Morin, Andrew, Soane, Caroline, Pierce, Angela, Sanford, Bridget, Jones, Kenneth L, Crespo, Michele, Zahedi, Shadi, Vibhakar, Rajeev, Mulcahy Levy, Jean M
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Basic and Translational Investigations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7236404/
https://ncbi.nlm.nih.gov/pubmed/32642704
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa051
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars